Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn’s disease in adults with moderate-to-severe disease

Table 1 Participant characteristics

	UC (N = 12)	CD (N = 12)
Age, mean (range), years	45 (31–59)	43 (18–61)
Gender, n (%)
Male	8 (67)	3 (25)
Female	4 (33)	9 (75)
Race, n (%)
Caucasian	9 (75)	6 (50)
African American	1 (8)	4 (33)
Hispanic	1 (8)	0 (0)
Mixed race	1 (8)	2 (17)
Work status, n (%)
Full-time	12 (100)	8 (67)
Part-time	0 (0)	1 (8)
Unemployed	0 (0)	2 (17)
Unable to work	0 (0)	1 (8)
Current treatment status, n (%)
Remission	9 (75)	9 (75)
Flare	3 (25)	3 (25)
Disease-specific treatment, n (%)^a
Anti-TNF	10 (83)	10 (83)
5-ASA	5 (42)	2 (17)
Anti-integrin	2 (17)	2 (17)
Other^b	8 (67)	11 (92)
Time since diagnosis, mean (range), months	103 (19–478)	103 (19–478)
Time since last flare, mean (range), months	8 (3–20)	8 (3–20)
Any other medical conditions, n (%)	5 (42)^c	5 (42)^d

ASA, aminosalicylic acid; CD, Crohn’s disease; TNF, tumor necrosis factor; UC, ulcerative colitis
^aParticipants could be receiving more than one therapy
^bOther treatments included azathioprine, balsalazide, corticosteroid, lorazepam, methotrexate, mercaptopurine, and probiotics
^cComorbidities reported by patients with UC: ankylosing spondylitis, asthma, gastroesophageal reflux disease, hypothyroidism, and type 2 diabetes (n = 1 for each)
^dComorbidities reported by patients with CD: high cholesterol and high blood pressure (n = 1); polycystic ovary syndrome and Wegener's granulomatosis (n = 1); Tourette’s syndrome (n = 1); cellulitis, asthma, and osteoarthritis (n = 1); and benign prostate condition, depression, back pain, and incontinence (n = 1)

ISSN: 1477-7525